Mutations in G protein-coupled receptors (GPCRs) that increase constitutive signaling activity can cause human disease. A de novo C-terminal mutation (R1465W) in the adhesion GPCR BAI2
INTRODUCTION
Adhesion G protein-coupled receptors (GPCRs) (aGPCRs) are an evolutionarily ancient yet enigmatic family of cell surface receptors. These proteins are widely expressed throughout the body, and loss-of-function mutations to a number of members are associated with human disease (Langenhan, Aust, & Hamann, 2013; O'Hayre et al., 2013) . For example, mutations in GPR56 (ADGRG1) result in the cortical malformation bilateral frontoparietal polymicrogyria (Piao et al., 2004) , mutations in GPR126 (ADGRG6) severely disrupt peripheral myelination (Ravenscroft et al., 2015) , mutations in VLGR1 (ADGRV1) cause deafness and retinitis pigmentosa (Weston, Luijendijk, Humphrey, Moller, & Kimberling, 2004) , and a mutation in EMR2 (ADGRE2) has been associated with vibratory urticaria (Boyden et al., 2016) .
To date, much of the focus on aGPCRs has been concentrated on their strikingly long extracellular amino (N) termini. These regions contain multiple domains, including adhesion folds, and nearly all of the more than 30 human aGPCRs contain a juxtamembrane GPCR Autoproteolysis Inducing (GAIN) domain. This hallmark aGPCR feature has autoproteolytic ability and can sever the receptors into two noncovalently associated protomers-an extracellular N-terminal fragment (NTF) and a C-terminal fragment (CTF) containing the archetypal seven transmembrane (7-TM) domain (Arac et al., 2012) . This autoproteolysis typically occurs in the endoplasmic reticulum, with the cleaved receptor protomers trafficking to the cell surface as a non-covalently associated complex (Krasnoperov et al., 2002) . BAI2 (ADGRB2; MIM# 602683) is one of three ADGRB subfamily receptors, which are also known as Brain-specific Angiogenesis Inhibitors 1-3 (BAI1-3) (Stephenson, Purcell, & Hall, 2014) . These receptors are most abundantly expressed in brain tissue, and BAI1 (ADGRB1) and BAI3 (ADGRB3) have been shown to have important roles at synapses (Bolliger, Martinelli, & Sudhof, 2011; Duman et al., 2013; Sigoillot et al., 2015) . At this point, much less is known about the function of BAI2. Mice lacking BAI2 were found to have no gross deficits, but did exhibit increased hippocampal neurogenesis and resilience to learned-helplessness behavior (Okajima, Kudo, & Yokota, 2011) .
While most aGPCRs remain orphan receptors with no known endogenous ligands, substantial progress has been made in understanding the activation mechanisms and signaling activity of many of these receptors. Interestingly, the extraordinarily long N-termini have an inhibitory effect on the constitutive signaling activity of the 7-TM domain in most aGPCRs studied thus far. For many aGPCRs, including BAI1 (Stephenson et al., 2013) and BAI2 (Okajima, Kudo, & Yokota, 2010) , and at least six other aGPCRs from five different sub-families ( , removal of the NTF results in a constitutively active receptor. One of the earliest reports of this phenomenon demonstrated that removing the NTF of BAI2 unveils the constitutive activity of the receptor, as measured by the nuclear factor of activated T cells (NFAT) luciferase reporter (Okajima et al., 2010) , but this study did not elucidate the G protein alpha subunit (G ) to which the receptor primarily couples.
Despite substantial progress in understanding how aGPCRs are activated, very little is known at this point about how these receptors are regulated. Previous reports have shown aGPCR C-terminal interactions with many different proteins containing PDZ domains (Kreienkamp, Zitzer, Gundelfinger, Richter, & Bockers, 2000; Paavola, Stephenson, Ritter, Alter, & Hall, 2011; Stephenson et al., 2013; Tobaben, Sudhof, & Stahl, 2000) and demonstrated that the constitutively active forms of BAI1 and GPR56 robustly co-immunoprecipitate with -arrestins (Paavola et al., 2011; Stephenson et al., 2013) . However, it remains unclear whether these interactions can fully explain how the receptors are internalized and undergo post-endocytic trafficking.
The present investigation into the signaling activity and regulation of BAI2 was spurred by work from the NIH Undiagnosed Diseases
Program (UDP) (Gahl et al., 2016) , which identified a de novo mutation (NM_001703.2(ADGRB2):c.4393C > T, p.Arg1465Trp) in a human patient suffering from progressive spastic paraparesis and other symptoms. We engineered the Arg to Trp substitution exhibited by this patient into BAI2 expression constructs and studied the effect of this mutation on receptor signaling, trafficking, and protein-protein interactions. Our studies revealed that this mutation increases BAI2 signaling activity and surface expression, and also disrupts interaction with the regulatory protein endophilin A1. Moreover, our results provided evidence that BAI2 predominantly couples to G z , with the mutation promoting enhanced G i coupling. (Figure 2A ) was constructed using Protter (Omasits, Ahrens, Muller, & Wollscheid, 2014) .
MATERIALS AND METHODS

Variant discovery
DNA constructs
Human ADGRB2 wild-type (WT) and R1465W plasmids were synthesized in pcDNA3.1 vectors (Genscript, Piscataway, NJ 
Western blot
Cell surface biotinylation
Twenty-four hours following tranfection with 2 g of receptor DNA, HEK-293T cells were washed in cold PBS+Ca 2+ and incubated with 5 mM Sulfo-NHS-Biotin (Thermo Scientific, Rockford, IL) or vehicle (PBS+Ca 2+ ) for 1 hr on ice. Biotinylation was quenched with 100 mM glycine and cells were harvested in cold PBS. Membranes were ruptured with a rapid freeze-thaw and pelleted at 17,000×g for 15 min at 4 • C. The membrane pellet was then re-suspended in 1% Triton X-100 buffer (25 mM HEPES, 150 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 1× HALT protease, and phosphatase inhibitor (Thermo)) and rotated end-over-end for 45 min to solubilize membrane proteins. The insoluble fraction was then pelleted at 17,000×g for 15 min at 4 • C and solubilizates were incubated with streptavidin agarose (Thermo) for 30 min to precipitate biotinylated proteins. Agarose was washed with 1% Triton buffer and proteins were eluted in 2× Laemmli buffer. Biotinylated proteins were detected via Western blot (above).
Co-immunoprecipitation
Cells were transfected with 3 g of receptor and 1 g of G protein
or arrestin and balanced with empty vector (EV) DNA. The following day, cells were harvested and membrane proteins were solubilized in 1% Triton X-100 buffer. Solubilizates were separated (above) and incubated with anti-HA agarose (Sigma), magnetic anti-Flag (Sigma), or protein A/G agarose (Thermo) beads with the indicated primary antibody for 1 hr end-over-end at 4 • C. Samples were then washed, eluted, and
Western blotted as described above.
Endogenous pull-down assay
Animal care and experimental procedures were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the protocol was approved by the Emory University Institutional Animal Care and Use Committee. Mice were euthanized by CO 2 asphyxiation. Brain tissue was harvested and homogenized in ice-cold 150 mM NaCl, 25 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1× fresh protease, and phosphatase inhibitor (HALT, Thermo) pH 7.4.
Large debris were cleared by centrifugation at 2,000×g at 4 • C and supernatant proteins were solubilized with 1% Triton X-100 (Sigma)
for 1 hr at 4 • C. The insoluble fraction was cleared by centrifugation at 17,000×g for 15 min at 4 • C and samples were normalized to 1 mg/ml with harvest buffer by BCA. A portion of the lysates were saved as "input" samples and the remainder was split between GST and GSTendo1-SH3 agarose beads and rotated at 4 • C overnight. The following day, beads were washed thoroughly with 1% Triton buffer, eluted with an equal volume of 2× Laemmli buffer, and 20 l was loaded for SDS-PAGE as described above.
Luciferase assays
HEK 
RESULTS
A mutation in ADGRB2 is associated with human disease
The patient was examined at 46 years of age. She indicated a history of progressive gait difficulties and urinary urgency since age 15.
A diagnosis of multiple sclerosis was entertained at age 18, and she began using a wheelchair at age 20. At age 23, neurological evaluation recorded mild bilateral optic nerve atrophy, bilateral nystagmus, and normal upper extremities strength but severe weakness and spasticity in the lower extremities. By age 35, weakness in upper extremities was evident. A suprapubic catheter was placed at age 41, and a baclofen pump was placed later the same year. She has been regarded as totally lihood that the mutation is deleterious (Kircher et al., 2014) . Thus,
given that the whole exome sequencing did not reveal any other mutations that might plausibly account for the observed pathology, we engineered this mutation into human BAI2 expression plasmids and explored whether the R1465W mutation might alter BAI2 function.
p.R1465W increases signaling activity and surface expression
To test potential effects of the BAI2 p.R1465W (RW) mutation on receptor insertion in the plasma membrane, we assessed total and cell surface expression of the full-length and truncated (ΔNT) forms of the both the WT and mutant receptors using a surface biotinylation approach. These studies revealed that the BAI2ΔNT p.R1465W mutant exhibited significantly increased surface expression over WT BAI2ΔNT ( Figure 3A ; one-sample t-test of surface expression normalized to WT BAI2ΔNT: BAI2ΔNT-RW = 2.06 ± 0.15, P = 0.0019, n = 5).
Total expression of BAI2ΔNT-RW also appeared to be increased, but was not statistically significant compared with WT BAI2ΔNT
(P = 0.0637).
To investigate the role of the p.R1465W mutation on BAI2 signaling activity, we over-expressed full-length and cleavage-mimicking (ΔNT)
forms of the WT and mutant receptors and assessed activation of a panel of luciferase reporters. Serum response factor (SRF) and NFAT were the most likely outputs based on homology to BAI1 (Stephenson et al., 2013 ) and a previous report about BAI2 (Okajima et al., 2010) .
We found that transfection of full-length BAI2 into HEK-293T cells did not result in activation of either reporter, either for the WT or mutant forms of the receptor ( Figure 3B , SRF data not shown). However, BAI2ΔNT robustly activated NFAT luciferase (one-way ANOVA, F (4, 15) = 66.61, Sidak post-hoc test vs. EV, P < 0.0001, n = 4), consistent with previous findings (Okajima et al., 2010) . Furthermore, we observed that the p.R1465W mutation significantly potentiated this signaling activity to NFAT luciferase (P = 0.0001 vs. BAI2ΔNT, n = 4).
BAI2 NT signals to NFAT luciferase via G and calcium channel activation
To shed light on the signaling pathway by which BAI2ΔNT activates NFAT luciferase, a number of different inhibitors were deployed. The BAI2ΔNT signal to NFAT luciferase was strongly inhibited by the G subunit inhibitor gallein (Lehmann, Seneviratne, & Smrcka, 2008) ( Figure 3C ; two-way ANOVA, main effect of inhibitor treatment, F (3, 56) = 10.06, Holm-Sidak post-hoc test BAI2ΔNT P < 0.001 vs. vehicle for gallein, BAI2ΔNT-RW P < 0.0001 vs. vehicle for gallein, n = 4).
Neither WT-nor mutant BAI2ΔNT-induced signaling was inhibited by the PLC inhibitor U73122, which blocks signaling downstream of G q -coupled receptors, and only signaling by the mutant receptor BAI2ΔNT-RW showed statistically significant sensitivity to pertussis toxin (PTX) ( Figure 3C ; BAI2ΔNT-RW P < 0.01 vs. vehicle, n = 4), which inhibits G i/o -mediated signaling.
To further assess the importance of G liberation on BAI2ΔNT signaling to NFAT luciferase, we co-expressed GRK2-CT ( ARKct), which can bind to and inhibit the activity of G subunits (Koch, Inglese, Stone, & Lefkowitz, 1993) . Like the gallein treatment, GRK2-CT inhibited the activity of BAI2ΔNT-RW ( Figure 3D ; two-way ANOVA, main effect of receptor × GRK2-CT interaction F (3, 9) = 7.378, Sidak posthoc test BAI2ΔNT-RW+GRK2-CT **P = 0.0016 vs. vehicle). Furthermore, we observed that the activation of NFAT luciferase by both WT and p.R1465W mutant BAI2ΔNT was almost completely blocked by the calcium channel inhibitor SKF96365 ( Figure 3D ; two-way ANOVA, main effect of SKF96365 F (1, 32) = 29.95, Holm-Sidak post-hoc test F I G U R E 3 BAI2 p.R1465W increases signaling activity and surface expression. (A) The R1465W mutation increased surface and total expression of BAI2ΔNT, as assessed by surface biotinylation (top, total protein expression bottom). Inset: one sample t-test compared with WT = 1.00 (Surface **P < 0.01 vs. B2ΔNT, n = 5). (B) BAI2ΔNT activated NFAT luciferase (one-way ANOVA, Sidak multiple comparisons BAI2ΔNT ****P < 0.0001 vs. empty vector (EV) condition, n = 4). The R1465W mutation had no effect on the full-length receptor (BAI2-RW) but significantly potentiated the activity of BAI2ΔNT (###P = 0.0001 vs. BAI2ΔNT, n = 4). C). The NFAT luciferase signal from BAI2ΔNT and BAI2ΔNT-RW was abolished by the G inhibitor gallein (second bar of each set; **P < 0.01 vs. B2ΔNT-vehicle condition, ****P < 0.0001 vs. BAI2ΔNT-RW vehicle n = 4). The mutant receptor was sensitive to pertussis toxin (PTX, 100 ng/ml) but the wild-type receptor was not (third bar of each set; ***P = 0.001 vs. BAI2ΔNT-RW vehicle condition, n = 4). Neither receptor was inhibited by 10 M U73122 (fourth bar of each set). (D) A transfectable G inhibitor, GRK2-CT (left), significantly inhibited the NFAT signal from BAI2ΔNT-RW (GRK2-CT-treated is second bar of each set; two-way ANOVA, BAI2ΔNT-RW **P = 0.001 vs. EV, n = 4). The calcium channel inhibitor SKF96365 (right, 50 M) completely blocked the NFAT signal from both receptors (SKF96365-treated is second bar of each set; two-way ANOVA, BAI2ΔNT **P > 0.01, BAI2ΔNT-RW ****P < 0.0001, n = 5) BAI2ΔNT **P = 0.0011 vs. vehicle, BAI2ΔNT-RW ****P < 0.0001 vs.
vehicle). These results indicate that the NFAT reporter activation by
BAI2ΔNT is almost entirely due to G liberation and activation of a calcium channel.
BAI2 couples to G z
NFAT luciferase is a common readout downstream of G q signaling (Hill, Baker, & Rees, 2001 ) but can also report activity from G 12/13 (Nishida et al., 2007) . In addition, G -mediated activity is most typically due to G i activation (Smrcka, 2008) . We have previously reported that ADGRB1/BAI1, a G 12/13 -coupled receptor, activates NFAT luciferase and therefore, given a high degree of similarity in the 7TM region, considered G q, G 12/13 and G i as the most likely candidates to be the cognate G protein for BAI2 (Kishore, Purcell, Nassiri-Toosi, & Hall, 2016) . However, we observed no interactions between BAI2ΔNT and G q or G 13 in co-immunoprecipitation experiments ( Figure 4A ). In contrast, we observed that the G i/o -family member G z robustly co-immunoprecipitated with BAI2ΔNT, with WT and p.R1465W mutant BAI2ΔNT immunoprecipitating G z to a similar extent ( Figure 4B ).
To further test the possibility that BAI2 might signal through G z coupling, we assessed BAI2ΔNT signaling to NFAT luciferase in the presence of co-transfection with the G z -specific regulator of G protein signaling RGS20 (RGSZ1) (Glick, Meigs, Miron, & Casey, 1998) . As a control, we co-expressed a related RGS protein, RGS2, which acts specifically on G q (Heximer, Watson, Linder, Blumer, & Hepler, 1997) . RGS2 had no effect on BAI2ΔNT or BAI2ΔNT-RW signaling to NFAT. In contrast, RGS20 strongly increased the activity of BAI2ΔNT and BAI2ΔNT-RW ( Figure 4C ; two-way ANOVA F (3, 36) = 54.56, P < 0.0001, n = 4, Tukey posthoc test BAI2ΔNT vs. mock P < 0.0001, BAI2ΔNT-RW vs. mock WT BAI2ΔNT and G i1 , but substantial co-immunoprecipitation of G i1 was observed with the BAI2ΔNT p.R1465W mutant ( Figure 4D ).
F I G U R E 4
Coupling of BAI2 to G proteins. (A) Among a panel of G protein subunits, only G z detectably co-immunoprecipitated with BAI2ΔNT (n = 4). (B) Both WT and R1465W forms of BAI2ΔNT co-immunoprecipitated with G z and there was no significant difference in their ability to interact (n = 5). (C) The G q-specific RGS protein RGS2 (second bar of each set) had no effect on WT or RW signaling, but the G z-specific RGS20 (third bar of each set) increased both BAI2ΔNT and BAI2ΔNT-RW activity (two-way ANOVA, Tukey test BAI2ΔNT-RGS20 ****P < 0.0001 vs. BAI2ΔNT-mock, BAI2ΔNT-RW ***P = 0.001 vs. BAI2ΔNT-RW-mock, n = 4). (D) Mutant BAI2ΔNT-RW interacted with G i1 but no interaction with the WT receptor was detected (n = 3)
p.R1465W mutation disrupts BAI2 interaction with endophilin A1
The activity and surface expression of GPCRs can be regulated by -arrestins, which bind to active receptors and often mediate their internalization and desensitization (Reiter & Lefkowitz, 2006) . Moreover, we have previously found that cleavage-mimicking forms of BAI1/ADGRB1 and GPR56/ADGRG1 strongly interact with -arrestins (Paavola et al., 2011; Stephenson et al., 2013) . Indeed, we observed that BAI2ΔNT robustly co-immunoprecipitates with -arrestin2, with the R1465W mutation having no effect on this interaction ( Figure 5A , n = 3).
The -arrestin-mediated pathway is not the sole mediator of GPCR internalization (Ferguson, 2001) . The membrane-binding BAR-and SH3-domain-containing protein endophilin A1 (SH3-GL2) has been shown to interact with certain GPCRs (Tang et al., 1999) and can mediate GPCR internalization in a rapid, clathrin-independent manner (Boucrot et al., 2015) . Therefore, we tested whether endophilins could interact with BAI2 by performing pull-down assays using the SH3 domain of endophilin A1 fused to glutathione-S-transferase (GST), or GST alone as a control, to pull down BAI2ΔNT. We found that WT BAI2ΔNT robustly interacted with the endophilin A1 SH3 domain, whereas interaction with BAI2ΔNT-RW was significantly reduced relative to WT ( Figure 5B ; unpaired t-test, WT binding = 6.46 ± 0.59 vs. RW = 0.48 ± 0.22, P < 0.0001, n = 4).
We hypothesized that if endophilin A1 is in fact an important regulator of BAI2 signaling, then co-transfection should limit the signaling activity of BAI2ΔNT. Indeed, we found that in 96-well format NFAT luciferase assays, as little as 2 ng of endophilin A1
DNA significantly reduced the signaling of BAI2ΔNT and BAI2ΔNT-RW ( Figure 5C ; two-way ANOVA, main effect of endo1 transfection F (1, 12) = 22.45, P = 0.0005, Sidak post-hoc test BAI2ΔNT and BAI2ΔNT-RW not significantly different from EV with endo1 cotransfection, n = 3). Both BAI2ΔNT WT and RW receptors were significantly inhibited by endophilin A1 over-expression, suggesting that even low levels of endophilin over-expression are sufficient to overcome the binding deficit of the mutant receptor.
The members of the brain-specific angiogenesis inhibitor (BAI1-3/ADGRB1-3) sub-family of receptors are highly enriched in brain tissue. Among the three endophilin A proteins, endophilin A1 has the most brain-enriched expression pattern (Kjaerulff, Brodin, & Jung, 2011) . To determine whether endophilin A1 can interact with endogenous BAI2 from brain tissue, we incubated GST-endoA1-SH3 domain with mouse brain lysates and probed pull-down fractions for BAI2. We observed a robust interaction with BAI2 ( Figure 5D , n = 3).
DISCUSSION
The aim of the present study was to investigate the signaling activity and regulation of the aGPCR BAI2 (ADGRB2) and assess the potential functional effects of a de novo disease-associated BAI2 mutation (p.R1465W) in a human patient. We found that this mutation in the WT BAI2ΔNT robustly interacted with the endophilinA1 SH3 domain but interaction with the mutant BAI2ΔNT-RW was significantly attenuated (one sample t-test, ****P < 0.0001 vs. BAI2ΔNT, n = 4). (C) Co-transfection of 2 ng of Endo1 DNA inhibited BAI2ΔNT (second bar of each set) and BAI2ΔNT-RW (third bar of each set) signaling activity to NFAT luciferase (two-way ANOVA, **P < 0.01 vs. EV, ****P < 0.0001 vs. EV, after Endo1 co-transfection no significant difference vs. EndoA1-EV, n = 3). (D) Endogenous BAI2 from mouse brain lysates interacts with the SH3 domain of endophilin A1 (n = 3) C-terminal region of BAI2 potentiates the receptor's signaling activity and enhances receptor surface expression. In agreement with a previous study, we found that a truncated form of BAI2, corresponding to the predicted BAI2 polypeptide after GAIN domain autoproteolysis and NT shedding, robustly activates the NFAT luciferase reporter (Okajima et al., 2010) . Most GPCRs that activate NFAT luciferase do so via coupling G q (Hill et al., 2001) , but the signaling to NFAT by BAI2 was found in the present study to be almost entirely dependent on G -mediated signaling. In terms of the G subunit involved, WT BAI2 exhibited a preferential coupling to the G i/o -family member G z , whereas the p.R1465W mutant exhibited significant coupling to both G z and G i , which may be related to the increased surface expression of the mutant receptor. Thus, the data presented here suggest two potentially connected mechanisms by which the p.R1465W mutation increases signaling activity: enhancement of receptor surface expression and increased coupling to specific G i/o -family proteins. (Robinson, Cohen, Zhukovsky, & Oprian, 1992) , and the substitution of aspartate for glycine at residue 578 in the luteinizing hormone receptor imparts constitutive activity, which can induce precocious puberty (Shenker et al., 1993) . Thus, the investigation of GPCR-activating mutations is important for understanding human disease as well as for shedding light on basic receptor biology (Thompson, Hendy, Percy, Bichet, & Cole, 2014) .
Gain-of-function mutations in other GPCRs
Effects of the p.R1465W mutation on BAI2 signaling
In our model (Figure 6 ), removal or rearrangement of the 911-aminoacid N-terminus of BAI2 allows the receptor to adopt its active conformation and associate with heterotrimeric G proteins. The data reported in the present study indicate that BAI2ΔNT signaling to the NFAT luciferase reporter is almost entirely mediated by G subunits, as co-expression of the GRK2-CT or treatment of cells with gallein strongly attenuated the signal. We also found that BAI2 can be F I G U R E 6 BAI2 signaling model. Shedding of the N terminus results in a constitutively active BAI2 (BAI2ΔNT). BAI2ΔNT couples to G z, which liberates G subunits leading to calcium influx and activation of the NFAT luciferase reporter. However, the R1465W mutation in BAI2ΔNT results in additional coupling to G i. The mutation also reduces interaction with endophilin A1 (EndoA1). BAI2ΔNT-RW is found at higher levels on the cell surface and is significantly more active than the WT receptor co-immunoprecipitated with G z , and furthermore observed that the G z -specific RGS protein, RGS20, significantly increased BAI2ΔNT signaling. Thus, these data implicate G z as a mediator of BAI2 signaling, although the RGS20 findings are somewhat paradoxical in that a G zspecific RGS protein should inhibit G z -mediated signaling rather than potentiate it. However, it is important to point out that BAI2ΔNT is a highly constitutively active receptor and thus is presumably highly desensitized. It may be the case that toning down the G z -mediated signal downstream of BAI2 results in less desensitization and therefore more sustained signaling, resulting in a paradoxical increase in the 48-hr luciferase reporter assay. Without an identified ligand or any other tool to activate BAI2 in a temporally controllable manner, overexpression of the cleavage-mimetic ΔNT form of BAI2 is the most effective way we have at present to study its signaling activity, so this represents a limitation of the present study. Alternatively, it is possible that activated G z may have unknown functions that limit signaling to NFAT, such that RGS20 relieves this inhibition and thereby potentiates the G -mediated NFAT activation. We demonstrated that nearly all of the activity that we observed to the NFAT reporter was dependent on calcium influx. A previous study found that G z can modulate ion channel function, including that of N-type calcium channels, in a PTXinsensitive manner (Jeong & Ikeda, 1998) . Therefore, inhibiting G z with RGS20 may relieve inhibition on calcium channels and increase signaling activity to NFAT luciferase.
Additional experiments will be required to more fully understand the mechanisms underlying the G -dependent Ca 2+ influx observed in the present study to be downstream of BAI2ΔNT in HEK cells.
SKF96365 is most commonly used as an antagonist of transient receptor potential canonical type channels, but at the concentration we utilized (50 M) it can also block several other types of calcium channels (Singh, Hildebrand, Garcia, & Snutch, 2010) . Interestingly, it was recently reported that the Drosophila homolog of the adhesion GPCR ADGRL1/latrophilin (dCIRL) modulates the action of a TRP channel to influence mechanosensation (Scholz et al., 2015) . Further studies will be required to determine how exactly BAI2 activation impacts calcium channel function and whether this regulation depends on direct channel association with G subunits.
Effects of the R1465W mutation on BAI2 trafficking
We observed that expression of BAI2ΔNT-p.R1465W is significantly higher than WT BAI2ΔNT on the cell surface, with the magnitude of this effect being comparable to the extent by which the mutation increases receptor signaling activity. Additionally, we found that association with -arrestins was unchanged by the p.R1465W mutation, which suggested other mechanisms may play a role in dictating BAI2 surface expression. Endophilin A1 was recently found to bind to a number of GPCRs and mediate their internalization via a pathway independent of -arrestins, ubiquitination or clathrin coat proteins (Boucrot et al., 2015) . We found that the SH3 domain of endophilin A1
avidly interacts with WT BAI2ΔNT, but interacts less robustly with the BAI2-RW mutant. However, the mutation does not completely abrogate binding, and overexpression of endophilin A1 in heterologous cells appeared in our studies to overcome the binding deficit and inhibit signaling by the RW mutant to an extent that was not significantly different from the effect on the WT receptor. Thus, the present studies identify endophilin A1 as a novel binding partner of BAI2, although it is uncertain whether the reduced binding of endophilin A1 by the BAI2 RW mutant contributes to the altered trafficking and activity of this receptor. A complicating factor in these studies is that there are three closely-related endophilins (A1-3) that are all widely expressed, so further studies will be needed to dissect the potential regulation of BAI2
by the various members of the endophilin family.
Potential clinical importance of ADGRB2
Mutations to GPCRs that increase constitutive activity are frequently toxic (Parnot, Miserey-Lenkei, Bardin, Corvol, & Clauser, 2002) . Our data indicate that the BAI2 R1465W mutation, which was discovered in a patient with a progressive neuromuscular disorder, significantly increases BAI2 signaling activity. Given the preferential expression of BAI2 in the nervous system, it is conceivable that heightened and/or prolonged activity from BAI2 could lead to neuromuscular disease. However, because these studies have been focused on a mutation found in a single patient to this point, it is impossible to make any definitive statements about causality. Still, given the lack of other explanations for the patient's pathology, combined with our data revealing that this mutation induces constitutive over-activity in a receptor expressed in the diseased areas, it is plausible that this mutation either underlies the pathology or acts as a modifier to exacerbate a pre-existing condition, such as multiple sclerosis, to result in an atypical presentation. In either case, BAI2 dysfunction would be implicated in neurodegeneration, and it would therefore be desirable to develop therapeutic strategies to normalize BAI2 activity. Deletion of Bai2 in mice has been reported to have no obvious negative consequences, with Bai2 null animals actually displaying increased hippocampal neurogenesis and exhibiting an antidepressant phenotype that includes resistance to learned helplessness behavior (Okajima et al., 2011) .
Together, these data suggest that BAI2 may be an attractive target for the development of antagonists that might have therapeutic value, and a recent report about the development of a small molecule antagonist for another adhesion GPCR (ADGRG1/GPR56) demonstrates the feasibility of this approach (Stoveken et al., 2016) . Thus, the pharmacological targeting on BAI2 will be of interest to pursue in future work, as will future studies, building on the findings presented here, aimed at shedding further light on the function(s) of BAI2 in vivo and the mechanisms by which BAI2 signaling is regulated.
